Experimental CAR T Therapy Completely Clears a Child’s Treatment-Resistant Liver Cancer
An experimental CAR T cell therapy led to the complete disappearance of metastatic liver cancer in a 3-year-old boy, offering rare hope for treating solid tumors. The case, reported in The New England Journal of Medicine, describes a durable remission without serious systemic side effects.
Chimeric Antigen Receptor T cell therapy involves removing a patient’s T cells, engineering them to recognize cancer cells and infusing them back into the body. While the approach has revolutionized treatment for several blood cancers, its success against solid tumors has remained limited.
How the child’s cancer progressed
The child was initially diagnosed with hepatoblastoma, a rare malignant liver cancer that usually affects very young children. Imaging revealed a large tumor in the left lobe of his liver, measuring 11.2 by 9.6 by 7.1 centimeters, along with evidence that the disease had already spread to his lungs and possibly his bones.
Standard treatment began with three cycles of intensive chemotherapy followed by surgery to remove the primary liver tumor. Surgeons later performed two additional operations to remove metastatic tumors from the lungs, but the cancer quickly returned with a new lung lesion, indicating aggressive, treatment-resistant disease.
The experimental GPC3-CAR T therapy
Following the relapse, the boy was enrolled in the CARE study, an early-phase clinical trial testing a novel CAR T therapy developed at Baylor College of Medicine. Researchers engineered his T cells to target glypican-3, or GPC3, a protein commonly overexpressed on liver cancer cells, including hepatoblastoma and some adult liver tumors.
To strengthen the treatment, the researchers added genes that produce the immune-stimulating proteins interleukin-15 and interleukin-21. Preclinical studies had suggested that these cytokines could extend CAR T cell survival and improve their ability to penetrate and destroy solid tumors.
The child received two outpatient infusions of the GPC3-CAR T product. Following the first dose, scans showed a partial response, while levels of alpha-fetoprotein — a blood marker associated with liver tumors — began to decline, indicating reduced cancer activity.
Complete remission without major toxicity
Eight weeks after the initial infusion, the boy received a second dose of the engineered T cells. Follow-up CT scans showed no visible signs of active disease, with only residual scarring remaining where tumors had previously been detected. The response was considered a complete remission.
At the 12-month follow-up, the child remained disease-free, with no radiological or clinical evidence of recurrence. Importantly, the treatment was administered entirely in an outpatient setting and did not cause severe systemic toxicities that can sometimes accompany CAR T therapies, including cytokine release syndrome or serious neurotoxicity.
Lead author David Steffin, a pediatric oncologist at Baylor College of Medicine, said the case demonstrates that a durable, complete response in a chemotherapy-resistant solid tumor can be achieved without intensive hospitalization. Co-author Andras Heczey, now at Seattle Children’s Hospital, emphasized the potential for treating other GPC3-positive solid tumors.
Broader implications for liver cancer
Liver cancer remains the third leading cause of cancer-related death worldwide, driven largely by hepatocellular carcinoma in adults. Although hepatoblastoma is rare, it is the most common liver cancer in children, and patients with relapsed or metastatic disease often face poor outcomes despite surgery and chemotherapy.
Progress in immunotherapies for liver malignancies has been slower than for some other cancers. Checkpoint inhibitors and targeted drugs have improved survival for certain adult patients, but complete responses and long-term remissions remain uncommon, particularly once the disease has spread.
The success of this single pediatric case does not establish that GPC3-targeted CAR T cells will work broadly, but it strengthens the rationale for testing more advanced cellular therapies against liver cancer. It also highlights the potential value of designing CAR constructs specifically adapted to solid tumors and the hostile microenvironments that protect them.
What comes next for the therapy
The CARE trial at Baylor College of Medicine continues to evaluate safety, dosing and early signs of efficacy in more children with relapsed or refractory hepatoblastoma and other GPC3-positive tumors. Parallel research is underway in the IMPACT trial at Seattle Children’s Hospital, which is also investigating modified CAR T approaches.
Researchers will need larger patient groups and longer follow-up to determine how durable these remissions are and whether serious delayed toxicities emerge. Regulators will also require rigorous evidence comparing outcomes with existing standards of care before broader approvals can be considered.
Still, the case adds to a growing body of evidence that next-generation CAR T therapies, enhanced with specific targets and immune-boosting cytokines, may begin to overcome long-standing barriers in solid tumor treatment. For families confronting aggressive childhood cancers, it represents a cautious but meaningful step forward.
The findings, detailed in The New England Journal of Medicine, add to ongoing global efforts to expand cellular immunotherapy beyond blood cancers and into more common and deadly solid tumors.
